BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106
ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171 for mesothelin-expressing cancers, with the company expecting to initiate clinical development during 2024.
QTTB: 9% | Q32 Bio shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $100 price target.